[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344460-105":3,"doc-detail-344460-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lincrna-bc7-as-a-modulator-of-olaparib-sensitivity-in-triple-negative-breast-cancer","LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer","","Triple-negative breast cancer (TNBC) remains challenging because of its aggressive behavior and frequent therapeutic resistance. While DNA repair roles of protein-coding genes are well established, regulatory functions of long non-coding RNAs, especially lincRNAs, are less defined. This study characterizes LincRNA-BC7 and investigates the LincRNA-BC7/miR-663a/BRCA1 axis in response to the PARP inhibitor Olaparib. Olaparib triggers selective cytotoxicity in BRCA1-deficient MDA-MB-231 cells, with LincRNA-BC7 downregulation and reciprocal BRCA1 upregulation. Bioinformatics suggests LincRNA-BC7 acts as a ceRNA by sequestering miR-663a, influencing PI3K-AKT and TP53 signaling and supporting LincRNA-BC7 as a biomarker and therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lincrna-bc7-as-a-modulator-of-olaparib-sensitivity-in-triple-negative-breast-cancer/344460/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lincrna-bc7-as-a-modulator-of-olaparib-sensitivity-in-triple-negative-breast-cancer/344460.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological mechanism does LincRNA-BC7 proposed to regulate in TNBC?","Question",{"text":63,"@type":64},"LincRNA-BC7 is suggested to act as a competing endogenous RNA (ceRNA) that sequesters miR-663a, thereby modulating downstream signaling linked to BRCA1 expression and DNA damage response pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Olaparib affect TNBC cells in the study?",{"text":68,"@type":64},"Olaparib induces selective cytotoxicity in BRCA1-deficient MDA-MB-231 cells while sparing non-cancerous HEK293 cells, accompanied by decreased LincRNA-BC7 and reciprocal increased BRCA1.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is the LincRNA-BC7/miR-663a/BRCA1 axis relevant for precision medicine?",{"text":72,"@type":64},"The study supports LincRNA-BC7 as a determinant of aggressive TNBC phenotype and treatment responsiveness, proposing the axis as a novel biomarker for precision risk stratification and a therapeutic target to improve outcomes in BRCA1-associated breast cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344460,1790932903,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923",8,"Article  \nLincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer  \nOlalekan Olatunde Fadebi 1,2, Babatunde Adebola Alabi 1,2, Richard Khanyile 1, Zodwa Dlamini 2 and Rahaba Marima 1,2, *  \nAcademic Editor: IvanaDela Serna  \nReceived: 18 April 2026  \nRevised: 20 May 2026  \nAccepted: 30 May 2026  \nPublished: 1 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa; u22493591@tuks.co.za (O.O.F.); [babatunde.alabi@up.ac.za](babatunde.alabi@up.ac.za) (B.A.A.); [richard.khanyile@up.ac.za](richard.khanyile@up.ac.za) (R.K.)  \n2 SAMRC Precision Oncology Research Unit (PORU), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield, Pretoria 0028, South Africa; zodwa.dlamini@up.ac.za  \n* Correspondence: [rahaba.marima@up.ac.za](rahaba.marima@up.ac.za)  \nAbstract  \nBackground: Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and the frequent emergence of therapeutic resistance. While the role of protein-coding genes in DNA repair is well-documented, the regulatory contributions of the non-coding genome, specifically long intergenic non-coding RNAs (lincRNAs), remain largely undefined. Objectives: In this study, we characterize the biological significance of LincRNA-BC7, a novel transcript identified within the breast cancer field effect. Methods: Through a combined in silico and in vitro approach, we investigated the transcriptional dynamics of the LincRNA-BC7 /miR-663a/BRCA1 axis in response to the PARP inhibitor, Olaparib. Results: Our results demonstrate that Olaparib induces selective cytotoxicityin BRCA1-deficient MDA-MB-231 cells while sparing non-cancerous HEK293 cells, a response accompanied by a significant downregulation of LincRNA-BC7 and a reciprocal upregulation of BRCA1 . Bioinformatics analysis through BLASTN, miRBase, and KEGG revealed that LincRNA-BC7 contains highly complementary binding sites for miR-663a, suggesting it functions as a competing endogenous RNA (ceRNA) or “molecular sponge.”Conclusions: By sequestering miR-663a, LincRNA-BC7 appears to modulate the expression of critical signaling nodes within the PI3K-AKT and TP53 pathways, thereby influencing cellular sensitivity to DNA-damaging agents. These findings suggest that LincRNA-BC7 is a key determinant of the aggressive TNBC phenotype and the response to PARP inhibition. Our study establishes the LincRNA-BC7/miR-663a axis as a novel biomarker for precision risk stratification and a promising therapeutic target to enhance treatment outcomes in BRCA1-associated breast cancers.  \nKeywords: breast cancer; LincRNA-BC7; BRCA1; olaparib; triple-negative breast cancer (TNBC); ceRNA; miR-663a; PARP inhibition  \n1. Introduction  \n1.1. Epidemiology of Global and Local Triple-Negative Breast Cancer  \nDue to its highly aggressive nature, lack of diverse therapeutic alternatives, and historically poor prognosis compared to other malignancies of the breast, triple-negative breast cancer (TNBC) presents a major obstacle in contemporary oncology. Diagnostically, this specific subtype is characterized by the simultaneous absence of estrogen receptors (ER),  \nprogesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), which effectively precludes the use of standard endocrine therapies or HER2-targeted agents that successfully manage other breast malignancies [1] . Because of this unique molecular profile, TNBC remains a primary driver of global cancer-related mortality and morbidity, standing as a critical area of need despite ongoing innovations in modern cancer research.  \nGlobally, breast cancer is the most frequently diagnosed cancer, with appro","cbCaiuSfcfeCEikk","https://ap.wps.com/l/cbCaiuSfcfeCEikk","pdf",2335983,16,"English","# Abstract\n## Objectives, Methods, Results, Conclusions\n# 1. Introduction\n## 1.1 Epidemiology of Global and Local Triple-Negative Breast Cancer\n## 1.2 Disparities and Risk Factors in Sub-Saharan Africa","[{\"question\":\"What biological mechanism does LincRNA-BC7 proposed to regulate in TNBC?\",\"answer\":\"LincRNA-BC7 is suggested to act as a competing endogenous RNA (ceRNA) that sequesters miR-663a, thereby modulating downstream signaling linked to BRCA1 expression and DNA damage response pathways.\"},{\"question\":\"How does Olaparib affect TNBC cells in the study?\",\"answer\":\"Olaparib induces selective cytotoxicity in BRCA1-deficient MDA-MB-231 cells while sparing non-cancerous HEK293 cells, accompanied by decreased LincRNA-BC7 and reciprocal increased BRCA1.\"},{\"question\":\"Why is the LincRNA-BC7/miR-663a/BRCA1 axis relevant for precision medicine?\",\"answer\":\"The study supports LincRNA-BC7 as a determinant of aggressive TNBC phenotype and treatment responsiveness, proposing the axis as a novel biomarker for precision risk stratification and a therapeutic target to improve outcomes in BRCA1-associated breast cancers.\"}]","LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer | PDF",1790053917,40,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7f506d310414c4d149671a018d4772e.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e17f7b6f0e08d73d6f3163a7523d3eb.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1fc401c134ec14ba5d261636f91306d.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3975459a987b83468b79b938449db04.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,134,139,143,146,151,154,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":98,"slug":142},7,"Healthcare","healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":144,"slug":145},30,"research-report",{"id":147,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":149,"slug":150},9,"Religion & Spirituality",20,"religion-spirituality",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":149,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":55,"slug":161},19,"General","general"]